244 related articles for article (PubMed ID: 26488033)
21. Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome.
Patterson AM; Wu T; Chua HL; Sampson CH; Fisher A; Singh P; Guise TA; Feng H; Muldoon J; Wright L; Plett PA; Pelus LM; Orschell CM
Radiat Res; 2021 Feb; 195(2):115-127. PubMed ID: 33302300
[TBL] [Abstract][Full Text] [Related]
22. Radioprotective Efficacy of Gamma-Tocotrienol in Nonhuman Primates.
Singh VK; Kulkarni S; Fatanmi OO; Wise SY; Newman VL; Romaine PL; Hendrickson H; Gulani J; Ghosh SP; Kumar KS; Hauer-Jensen M
Radiat Res; 2016 Mar; 185(3):285-98. PubMed ID: 26930378
[TBL] [Abstract][Full Text] [Related]
23. The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice.
Goldman DC; Alexeev V; Lash E; Guha C; Rodeck U; Fleming WH
Radiat Res; 2015 Mar; 183(3):338-44. PubMed ID: 25738896
[TBL] [Abstract][Full Text] [Related]
24. Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome.
Harrold J; Gisleskog PO; Perez-Ruixo JJ; Delor I; Chow A; Jacqmin P; Melhem M
Clin Transl Sci; 2020 Jul; 13(4):807-817. PubMed ID: 32112517
[TBL] [Abstract][Full Text] [Related]
25. The role of biosimilar granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic stem cell transplantation.
Severson CC
Can Oncol Nurs J; 2015; 25(4):443-54. PubMed ID: 26897866
[TBL] [Abstract][Full Text] [Related]
26. Mobilized progenitor cells as a bridging therapy for radiation casualties: a brief review of tocopherol succinate-based approaches.
Singh VK; Singh PK; Wise SY; Seed TM
Int Immunopharmacol; 2011 Jul; 11(7):842-47. PubMed ID: 21296698
[TBL] [Abstract][Full Text] [Related]
27. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
Maul JT; Stenner-Liewen F; Seifert B; Pfrommer S; Petrausch U; Kiessling MK; Schanz U; Nair G; Mischo A; Taverna C; Schmidt A; Bargetzi M; Stupp R; Renner C; Samaras P
J Clin Apher; 2017 Feb; 32(1):21-26. PubMed ID: 27001243
[TBL] [Abstract][Full Text] [Related]
28. FDA advisers recommend approval of biosimilar filgrastim.
Traynor K
Am J Health Syst Pharm; 2015 Feb; 72(4):262, 264. PubMed ID: 25631830
[No Abstract] [Full Text] [Related]
29. Biosimilars G-CSF versus originator G-CSF in post allotransplant recovery. A case-control study.
Targhetta C; Baronciani D; Capasso M; Depau C; Tandurella I; Giuseppina Corona M; Angelucci E
Am J Hematol; 2016 Feb; 91(2):E7-8. PubMed ID: 26596244
[No Abstract] [Full Text] [Related]
30. Promising role of filgrastim and α-tocopherol succinate in amelioration of gastrointestinal acute radiation syndrome (GI-ARS) in mice.
Gheita HA; El-Sabbagh WA; Abdelsalam RM; Attia AS; El-Ghazaly MA
Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1537-1550. PubMed ID: 31350581
[TBL] [Abstract][Full Text] [Related]
31. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
32. Tbo-Filgrastim: A Review in Neutropenic Conditions.
Blair HA; Scott LJ
BioDrugs; 2016 Apr; 30(2):153-60. PubMed ID: 27023705
[TBL] [Abstract][Full Text] [Related]
33. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
[TBL] [Abstract][Full Text] [Related]
34. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
Qureshi ZP; Nagai S; Bennett CL
JAMA Oncol; 2019 Mar; 5(3):297-298. PubMed ID: 30508013
[No Abstract] [Full Text] [Related]
35. Safety and Biosimilarity of ior
Licollari A; Riddle K; Taylor SR; Ledon N; Bolger GT
J Pharm Sci; 2017 Jun; 106(6):1475-1481. PubMed ID: 28238900
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.
Kobayashi T; Kamada I; Komura J; Toyoshima S; Ishii-Watabe A
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):917-924. PubMed ID: 28612945
[TBL] [Abstract][Full Text] [Related]
37. Radiation Nephropathy in a Nonhuman Primate Model of Partial-body Irradiation with Minimal Bone Marrow Sparing-Part 1: Acute and Chronic Kidney Injury and the Influence of Neupogen.
Cohen EP; Hankey KG; Farese AM; Parker GA; Jones JW; Kane MA; Bennett A; MacVittie TJ
Health Phys; 2019 Mar; 116(3):401-408. PubMed ID: 30608245
[TBL] [Abstract][Full Text] [Related]
38. The evolution of value with filgrastim in oncology.
Cornes P; Krendyukov A
Future Oncol; 2019 May; 15(13):1525-1533. PubMed ID: 30835142
[TBL] [Abstract][Full Text] [Related]
39. Cytokine-based treatment of accidentally irradiated victims and new approaches.
Hérodin F; Drouet M
Exp Hematol; 2005 Oct; 33(10):1071-80. PubMed ID: 16219528
[TBL] [Abstract][Full Text] [Related]
40. Use of molecularly-cloned haematopoietic growth factors in persons exposed to acute high-dose, high-dose rate whole-body ionizing radiations.
Gale RP; Armitage JO
Blood Rev; 2021 Jan; 45():100690. PubMed ID: 32273121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
